Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
- Heidi VN Küsters-Vandevelde†1Email author,
- Annelieke ECAB Willemsen†2,
- Patricia JTA Groenen3,
- Benno Küsters3,
- Martin Lammens3, 7,
- Pieter Wesseling1, 3, 6,
- Melika Djafarihamedani3,
- Jos Rijntjes3,
- Hans Delye5,
- Michel A Willemsen4,
- Carla ML van Herpen2 and
- Willeke AM Blokx3
© Küsters-Vandevelde et al.; licensee BioMed Central Ltd. 2014
Received: 30 January 2014
Accepted: 1 April 2014
Published: 8 April 2014
Neurocutaneous melanosis (NCM) is a rare congenital disorder characterized by the association of large and/or multiple congenital melanocytic nevi (CMN) of the skin with melanocytic lesions of the leptomeninges, including melanocytosis. Leptomeningeal melanocytosis carries a poor prognosis once neurological symptoms develop. Despite surgery, which is often not radical, few other treatment options exist. Recently, it was demonstrated that early embryonic, post-zygotic somatic mutations in the NRAS gene are implicated in the pathogenesis of NCM.
In this report, we present a 13-year-old boy with NCM and progressive symptomatic leptomeningeal melanocytosis. A somatic NRASQ61K mutation was present in both CMN as well as the melanocytosis. Despite repeated surgery, the patient showed clinical progression. Therefore, treatment with MEK162, a MEK inhibitor, was started on compassionate use base. The patient died only five days later, i.e. too early to expect a clinical effect of MEK162 therapy. We therefore studied the effect of MEK162 at the protein level in the leptomeningeal tumor by immunohistochemical and Western Blot analyses using Ki67 and pERK antibodies. We observed lower MIB-1 expression and lower pERK expression in the post-treatment samples compared to pre-treatment, suggesting a potential effect of MEK inhibiting therapy. Further studies are needed to determine whether MEK inhibitors can effectively target NRAS-mutated symptomatic NCM, a rare but potentially fatal disease.
KeywordsNRAS Neurocutaneous melanosis Leptomeningeal melanocytosis Targeted therapy MEK inhibitor MEK162
Neurocutaneous melanosis (NCM) is a rare congenital disorder first described by Rokitansky in 1861, in which affected patients have an increased number of melanocytes in the leptomeninges of the central nervous system (CNS) and the skin[1, 2]. The diagnostic criteria for NCM, originally proposed by Fox and revised by Kadonaga and Frieden include large or multiple congenital melanocytic nevi (CMN) of the skin associated with leptomeningeal melanocytosis or (primary) leptomeningeal melanoma. The pathogenesis of NCM has not been fully elucidated but it is thought to represent a congenital error during early embryonic migration of melanocytes.
Leptomeningeal melanocytosis consists of a diffuse proliferation of histologically benign appearing melanocytes in the leptomeninges, without evident invasion of the CNS. Patients can develop neurological symptoms due to impaired CSF drainage resulting in increased intracranial pressure and/or due to mass effect on the brain or spinal cord. Even in the absence of malignant progression, leptomeningeal melanocytosis carries a poor prognosis once neurological symptoms develop[1, 5].
So far, surgical resection of the leptomeningeal tumor is the treatment of choice, but complete resection is often impossible. In addition, the value of chemotherapy and radiotherapy is not clear. Recently, a few studies have demonstrated that early embryonic, post-zygotic somatic mutations in the NRAS gene are implicated in the development of NCM[6, 7].
In this case report, we present a 13-year-old boy with NRAS-mutated leptomeningeal melanocytosis in the context of NCM. Despite repeated surgery, the patient showed clinical progression and treatment with MEK162, a MEK inhibitor, was started on compassionate use. Unfortunately, the patient died only five days after start of this treatment, i.e. too early to expect a clear clinical effect. We therefore proceeded with investigating the potential effect of MEK162 at the protein level by immunohistochemical and Western Blot analyses using Ki67 and pERK antibodies. We observed lower MIB-1 expression and lower pERK expression in the post-treatment melanocytosis samples compared to the pre-treatment sample, suggesting a potential effect of MEK inhibiting therapy.
Histopathological examination indeed showed leptomeningeal melanocytosis and thus confirmed the clinical diagnosis of NCM. Mutation analysis revealed a mutation in exon 3 at codon 61 of NRAS (c.1818C > A (p.(Gln61Lys) alias “Q61K”). On revision, the previously removed congenital nevi from both legs, left arm, right shoulder and right eyebrow were melanocytic nevi without signs of malignancy. NRAS mutation analysis of one of them showed an identical NRAS mutation as in the leptomeningeal melanocytosis. The NRAS mutation was absent in normal skin, thereby excluding an NRAS germ-line mutation. After surgery, the patient initially improved. In the following months, however, neurological symptoms increased and repeated imaging showed progressive leptomeningeal lesions around the brain and spinal cord with (further) compression of these structures and hydrocephalus (Figure 1C-D). In an attempt to relieve some of the symptoms, a ventriculo-peritoneal shunt was placed in the right lateral ventricle. However, the fourth ventricle enlarged again due to aquaduct stenosis. Hence, aquaduct stenting was performed. Unfortunately, this could not prevent further deterioration. At that time there were no neurosurgical options left and we refrained from radiotherapy since it was unlikely that irradiation would provide rapid clinical benefit.
In view of the previously described beneficial effect of MEK162 in NRAS-mutated metastatic melanoma, and knowing that our patient carried an activating NRAS mutation in his leptomeningeal melanocytosis lesion, we considered treatment of our patient with MEK162. Novartis agreed to supply MEK162 on compassionate use base, and after screening for eligibility and parental consent treatment with MEK162 45 mg BID was started.
In the following days however, the patient was readmitted to the hospital because of further deterioration with progressive general weakness and stridor. He had papules on the chest, consistent with mild skin toxicity due to MEK162. Cerebral MRI confirmed disease progression. Five days after starting MEK162 treatment, the boy died due to central neurogenic respiratory failure. The parents gave permission to perform autopsy.
Autopsy findings and histology
Microscopically, a leptomeningeal proliferation consisting of melanocytic cells was seen (Figure 3B,D-E), confirmed by staining for S100, Melan-A and HMB-45. The melanocytic cells were ovoid and monotonous, with little cytonuclear atypia (Figure 3E) and occasionally some cytoplasmic melanin pigment. Necrosis was absent and mitotic activity was low. Extension of melanocytic cells in the perivascular Virchow Robin spaces of the brain (Figure 3B) and spinal cord was present, without frank invasion of the CNS parenchyma. Compression of the brain stem by the diffuse leptomeningeal melanocytosis, causing respiratory insufficiency by increased pressure, was considered as the cause of death. Histological examination of the nevi at autopsy and revision of previously removed CMN, demonstrated compound melanocytic nevi with congenital features, without signs of malignancy.
Furthermore, 75% of tumor cells in the pre-treatment sample were positive in the pERK stain versus 25% of tumor cells in the post-treatment sample (Figure 4E, pre-treatment, and Figure 4F pERK staining post-treatment).
An identical mutation in exon 3 at codon 61 of NRAS (c.1818C > A (p.(Gln61Lys) alias “Q61K”) was present in the melanocytosis tissue removed at surgery and in one of the congenital nevi removed in the past, while normal skin did not reveal an NRAS mutation, thereby excluding an NRAS germ-line mutation. We also tested the melanocytosis sample for mutations in codon 600 of BRAF and for oncogenic mutations in codon 209 of the GNAQ and GNA11 genes, as the latter are present in adult cases of primary leptomeningeal melanocytic neoplasms[8, 9]. Mutations in these genes were absent.
Unfortunately, the brain specimen before MEK162 treatment was insufficient for Western Blot analysis. In the brain sample that was obtained by autopsy the Western Blot showed presence of total ERK, but not of pERK, which is in line with the immunohistochemical staining results. See Figure 4G and4H.
This case report describes a 13-year-old boy, known since birth with multiple large CMN, who developed progressive neurological symptoms due to leptomeningeal melanocytosis. The association of large and/or multiple CMN of the skin with melanocytic lesions of the CNS is known as NCM. The CNS manifestations in NCM include leptomeningeal melanocytosis or melanoma, but also melanotic abnormalities with intraparenchymal deposits of melanin as well as associations with CNS malformations have been reported[1, 10–12].
Leptomeningeal melanocytosis has a poor prognosis once neurological symptoms develop and treatment mostly includes surgical interventions to reduce intracranial pressure. The efficacy of irradiation and chemotherapy for this disorder is unclear.
Recently, it was demonstrated that early embryonic, post-zygotic somatic mutations in the NRAS gene are implicated in the development of NCM and childhood melanoma of the CNS[6, 7, 9]. Thus far, all primary childhood melanomas of the CNS and leptomeningeal melanocytosis were found to harbor somatic NRAS mutations: in the 6 cases reported in literature, including the present case, a codon 61 mutation in NRAS was demonstrated (1 case Q61L, 3 cases Q61R, 2 cases Q61K)[6, 7, 9]. It can be hypothesized that early during embryogenesis a melanocyte precursor acquires a somatic NRAS mutation resulting in a ‘mosaic’ pattern of melanocytes that colonize the skin and leptomeninges. This could explain the presence of an identical somatic NRAS mutation in the CMN as well as in the leptomeningeal melanocytosis in this patient.
Recently, a non-randomized phase-2 study has demonstrated that MEK162 shows activity in NRAS-mutated melanoma. In addition, we previously reported on a mouse model in which embryonic induction of oncogenic NRAS mutation led to NCM-like disease in mice with development of primary CNS melanoma. In that study, we were able to demonstrate that cells derived from the primary CNS melanomas in the mice displayed constitutive ERK activity and that those cells were sensitive to the MAP–ERK kinase (MEK) inhibitors PD184352, U0126, and AZD6244. Such information led us to start MEK162 treatment on compassionate use base in our patient. Unfortunately, the patient passed away only five days later and we were not able to assess the clinical effect of MEK162 treatment. However, immunohistochemical analysis revealed that after MEK162 treatment proliferation as well as pERK expression was lower in the leptomeningeal melanocytosis as compared to the pre-treatment situation. Of course these findings in a single patient should be interpreted with caution. Still, our findings are in line with those of another recent case report, reporting effect of vemurafenib in a patient with diffuse leptomeningeal melanoma metastasis carrying an activating BRAF mutation.
In the largest phase 2 study of MEK162 in melanoma patients so far, MEK162 was well tolerated overall. The most common toxicities were skin- and gastrointestinal-related and fluid retention. These toxicities were generally mild and well manageable. More severe adverse events were uncommon; the most common grade 3–4 adverse event was an asymptomatic rise in creatine phosphokinase. So far, no increased risk of paradoxical tumor development has been observed, as has been described with BRAF inhibitors. Long-term data on safety of MEK162 are still awaited however.
In conclusion, we report a case of NCM with progressive symptomatic leptomeningeal melanocytosis harboring a somatic NRASQ61K mutation that was experimentally treated with MEK162. We observed a decrease in proliferation as well as a decrease in pERK expression in the post-treatment melanocytosis samples as compared to a pre-treatment sample, suggesting an effect of MEK inhibiting therapy. However, further studies are needed to determine whether MEK inhibitors can effectively target NRAS-mutated NCM. This is important considering the often fatal course of symptomatic NCM and the limited treatment options that are available for this disorder.
Written informed consent was obtained from the mother of the patient for publication of this Case report and of accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of Acta Neuropathologica Communications.
Central nervous system
Congenital melanocytic nevus.
This work was supported with a grant from the Koppie-Au foundation. We thank Mirthe Erkens from the Department of Cell Biology, Radboud University Nijmegen, for providing us with pERK antibodies.
- Kadonaga JN, Frieden IJ: Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol 1991, 24: 747–755. 10.1016/0190-9622(91)70115-IView ArticlePubMedGoogle Scholar
- Rokitansky: Ein ausgezeichneter Fall von Pigment-Mal mit ausgebreiteter Pigmentirung der inneren Hirn- und Rueckenmarkshaute. Allgemeine Wiener Medizinische Zeitung 1861, 15: 113–116.Google Scholar
- Fox: Neurocutaneous melanosis. In Handbook of Clinical Neurology. Edited by: Vinken PJ, Bruyn GW. New York: Elsevier; 1972:414–428.Google Scholar
- Brat DJ, Perry A: Melanocytic lesions. In WHO Classification of Tumours of the Central Nervous System. 4th edition. Edited by: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. Lyon: IARC; 2007:181–183.Google Scholar
- Brunsvig KL, Zenobi M, Rilliet B, El Hassani Y, de Haller R, Ansari M, Lobrinus JA, Hanquinet S, Fluss J: Primary leptomeningeal melanocytosis in a 10-year-old girl: a challenging diagnosis with a poor prognosis. J Child Neurol 2011, 26: 1444–1448. 10.1177/0883073811409749View ArticlePubMedGoogle Scholar
- Pedersen M, Kusters-Vandevelde HV, Viros A, Groenen PJ, Sanchez-Laorden B, Gilhuis JH, van Engen-van Grunsven IA, Renier W, Schieving J, Niculescu-Duvaz I, Springer CJ, Kusters B, Wesseling B, Blokx WA, Marais R: Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov 2013, 3: 458–469. 10.1158/2159-8290.CD-12-0464View ArticlePubMedPubMed CentralGoogle Scholar
- Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, Hing S, Chalker J, McKenzie K, Abu-Amero S, Sater O, Chanudet E, Palmer R, Morrogh D, Stanier P, Healy E, Sebire NJ, Moore GE: Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol 2013, 9: 2229–2236.View ArticleGoogle Scholar
- Kusters-Vandevelde HV, Klaasen A, Kusters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger G, Wesseling P, Blokx WA: Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 2010, 3: 317–323.View ArticleGoogle Scholar
- Gessi M, Hammes J, Lauriola L, Dorner E, Kirfel J, Kristiansen G, Zur Muehlen A, Denkhaus D, Waha A, Pietsch T: GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system. Neuropathol Appl Neurobiol 2013, 4: 417–425.View ArticleGoogle Scholar
- Kinsler VA, Paine SM, Anderson GW, Wijesekara DS, Sebire NJ, Chong WK, Harkness W, Aylett SE, Jacques TS: Neuropathology of neurocutaneous melanosis: histological foci of melanotic neurones and glia may be undetectable on MRI. Acta Neuropathol 2012, 3: 453–456.View ArticleGoogle Scholar
- Demirci A, Kawamura Y, Sze G, Duncan C: MR of parenchymal neurocutaneous melanosis. Am J Neuroradiol 1995, 16: 603–606.PubMedGoogle Scholar
- Schreml S, Gruendobler B, Schreml J, Bayer M, Ladoyanni E, Prantl L, Eichelberg G: Neurocutaneous melanosis in association with Dandy-Walker malformation: case report and literature review. Clin Exp Dermatol 2008, 33: 611–614. 10.1111/j.1365-2230.2008.02745.xView ArticlePubMedGoogle Scholar
- Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14: 249–256. 10.1016/S1470-2045(13)70024-XView ArticlePubMedGoogle Scholar
- Schafer N, Scheffler B, Stuplich M, Schaub C, Kebir C, Rehkamper C, Mack F, Niehusmann P, Simon M, Greschus S, Kuchelmeister K, Herrlinger U, Glas M: Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol 2013, 31: e173-e174. 10.1200/JCO.2012.46.5773View ArticlePubMedGoogle Scholar
- Sloot S, Fedorenko IV, Smalley KS, Gibney GT: Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe? Expert Opin Pharmacother 2014, 15: 589–592. 10.1517/14656566.2014.881471View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.